Amneal acquires Kashiv BioSciences for $750M upfront; raises FY2026 guidance on strong Q1

Amneal Pharmaceuticals, Inc.

Acquisition of Kashiv: $375M cash + $375M equity (28.9M shares) at close; up to $350M regulatory milestones plus royalties.
Expected close H2 2026; subject to shareholder and regulatory approvals; creates global biosimilar platform.
Preliminary Q1 2026 results strong; standalone FY2026 guidance raised (details per press release).
Transaction expected to deliver $400M-$500M in financial benefits; minimal impact on leverage.
Restrictive covenants agreements with co-CEOs Chirag and Chintu Patel from closing through fifth anniversary.

item 1.01 item 2.02 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amneal Pharmaceuticals, Inc. updated its the first quarter ended March 31, 2026 guidance (raised).

Period: the first quarter ended March 31, 2026
Guidance: raised
Result: preliminary results

Exact text from the filing

On April 22, 2026, the Company issued a press release announcing its preliminary results for the first quarter ended March 31, 2026.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Amneal Pharmaceuticals, Inc. entered into Membership Interest Purchase Agreement with Kashiv BioSciences, LLC valued at $375,000,000 in cash (effective 2026-04-21).

Action: entry
Agreement: merger
Counterparty: Kashiv BioSciences, LLC
Value: $375,000,000 in cash
Effective: 2026-04-21

Exact text from the filing

On April 21, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Amneal”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”), pursuant to which, among other matters and on the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to acquire from the Sellers 100% of the outstanding membership interests of Kashiv (the “Acquisition”).

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-168231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.